GRI Bio, Inc. (GRI): Price/Earnings to Growth Multiple
GRI Bio, Inc. (GRI) generates revenue through grants, focusing on the development of drugs for autoimmune pathologies. The PEG ratio visualizes this stage, where the parameter value equals 0.00. The company's potential is based on inelastic demand for liver fibrosis treatment, while intellectual property protection and stringent FDA requirements create a significant barrier to entry for new players.
Analytical breakdowns for GRI Bio, Inc. (GRI)
- price and consensus price forecast:
- stock exchange capitalization data:
- book value of equity indicators:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
GRI - Net Income|Expected Net Income GRI Bio, Inc.|GRI - P/E Multiple|Future Price to Earnings GRI Bio Corporation|GRI - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio GRI Bio Corp|GRI - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months GRI Bio|GRI - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months gribio.com|GRI - Earnings growth in current year|Consensus forecast of earnings per share growth for next year GRI Bio, Inc.
General company analysis:GRI Bio, Inc.
Searching for undervalued assets requires aligning business value with profit dynamics, which is critically important for GRI Bio, Inc. (GRI) within the NKT-cell immunotherapy segment during its expansion into the global chronic pathology market. The current value of 0.00 on a weighted P/E relative to profit growth rates reflects the PEG ratio: if the indicator is below one, the market is undervaluing the company's potential, ignoring the scaling rates of its fundamental metrics.
Competitors of GRI Bio, Inc.
Growth-Adjusted Market Cap to Net Income argenx N.V.|Price/Earnings to Growth Ratio BioNTech Group BNTX|ABVX - Price/Earnings to Growth Multiple|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|IMVT (Immunovant) - Price/Earnings to Growth Multiple|Kiniksa Pharmaceuticals, Ltd. (KNSA) - PEG Multiple|Price/Earnings to Growth Ratio Grifols Group|Growth-Adjusted P/E Ratio ADPT (Adaptive Biotechnologies Inc.)|PEG Multiple CLDX|AUPH - Price to Earnings Adjusted for Growth Rate|PEG Multiple BCRX (BioCryst Pharmaceuticals)|Price to Net Income Growth Ratio Vera Therapeutics Inc|DNTH - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio PHVS (Pharvaris Pharma)|ABCL: PEG Multiple|TRML - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple PGEN|PHAR: Growth-Adjusted Payback Ratio|PEG Multiple NKTR|Price/Earnings to Growth Ratio UPB (Upstream Pharma)|PEG Multiple ZBIO (Zenas Biopharma Inc)|Growth-Adjusted Market Cap to Net Income immunome.com (IMNM)|GOSS - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate KalVista Pharma|SEPN (Septerna Corp) - Price/Earnings to Growth Multiple|Pieris Corp - Growth-Adjusted Payback Ratio|SVRA (Savara Inc.) - PEG Multiple|rigel.com (RIGL) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio AnaptysBio (ANAB)|Astria Therapeutics Inc - Growth-Adjusted P/E Ratio|PEG Multiple ENGN (enGene Bio)|RAPT - Price/Earnings to Growth Multiple|JBIO: Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income aclaristx.com ACRS|KYTX: PEG Multiple|Price to Net Income Growth Ratio Tiziana Life Sciences Ltd. TLSA|Price/Earnings to Growth Ratio Cabaletta Bio, Inc|VTYX: Growth-Adjusted Payback Ratio|PEG Multiple THTX|Growth-Adjusted Market Cap to Net Income avalotx.com|Price/Earnings to Growth Ratio Eledon Pharmaceuticals, Inc. ELDN|AGEN (Agenus, Inc.) - Market Cap to Earnings and Growth Ratio|Climb Bio, Inc. - PEG Multiple|Growth-Adjusted Payback Ratio ZURA (zurabio.com)|ATYR: PEG Multiple|Adagene Inc. (ADAG) - PEG Multiple|Price/Earnings to Growth Ratio ImageneBio|STTK: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Equillium, Inc. (EQ)|Price/Earnings to Growth Multiple connectbiopharm.com CNTB|PEG Multiple IMUX (Immunic)|PEG Multiple Atara Biotherapeutics, Inc. ATRA|IFRX: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio XFOR (X4 Pharmaceuticals Inc.)|ACET: PEG Multiple|CELU - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio INmune Bio, Inc.|Price/Earnings to Growth Multiple barinthusbio.com (BRNS)|Price/Earnings to Growth Ratio Kezar Life Sciences, Inc. (KZR)|Price/Earnings to Growth Multiple SAB Biotherapeutics Inc. SABS|Akari Therapeutics plc - Price/Earnings to Growth Multiple|PEG Multiple Enlivex Therapeutics Ltd ENLV|QTTB - Price/Earnings to Growth Ratio|GOVX (geovax.com) - Growth-Adjusted P/E Ratio|EDSA: PEG Multiple|Price to Earnings Adjusted for Growth Rate iBio Inc (IBIO)|CARM (Carisma Therapeutics Inc) - PEG Multiple|XTLB - Price to Net Income Growth Ratio|Price/Earnings to Growth Ratio Bolt Biotherapeutics (BOLT)|HCWB (hcwbiologics.com) - Growth-Adjusted Payback Ratio|PEG Multiple APVO (Aptevo Therapeutics Inc.)|Growth-Adjusted Market Cap to Net Income aimimmuno.com (AIM)|ADTX: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio XRTX (XORTX Corp)|HIND: PEG Multiple|REVB (revbiosciences.com) - Price/Earnings to Growth Ratio|INDP (Indaptus Therapeutics, Inc.) - PEG Multiple|Scinai Immunotherapeutics Ltd (SCNI) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio CalciMedica, Inc. (CALI)|AFMD - Price to Earnings Adjusted for Growth Rate|Allakos - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio HOOK|IGM Bio - PEG Multiple|Growth-Adjusted Market Cap to Net Income iTeos Therapeutics Inc ITOS|Ocean Bio (OCEA) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio TCBP|THRD (Third Harmonic Bio) - PEG Multiple
